Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

preDiCT · Computational Prediction of Drug Cardiac Toxicity

FP7Status: CLOSED1 June 200831 May 2011EU funding €4,100,000

Many drugs fail to reach the market because of side effects on the heart. The principal objective of this proposal is to create an advanced computational technology for in silico assessment of the efficacy and safety of specific drugs [ICT-2007.5.3(c) (3)], i.e. an open environment comprising validated computational models, tools and numerical methods that will enable simulations of drug actions on the electrophysiology of the human heart. Such simulations will involve modelling of drug interactions at the molecular and cellular level, will extend current technology to enable prediction of the effects of those interactions on the dynamics of the whole heart, and will lead to an understanding of how genetic factors can be used to assess patient-specific risk profiles. This requires a multi-level systems approach, based on multi-scale, multi-physics methods, including computations on adaptive spatial grids and multi-grid time integration. Computations on realistic models at appropriate spatial and temporal scales are currently not feasible, so we will investigate new algorithms and their implementation on high-performance platforms, including a new generation of petaflop computers, to achieve ‘faster than real-time’ simulation. These tools form part of the infrastructure required to simulate the physiology of major organ systems, thereby contributing to the goal of creating the Virtual Physiological Human (VPH) [ICT-2007.5.3]. The balanced team in this project, including founders of the Human Physiome Project, has decades of experience in the experimental study and modelling of the electrophysiology and mechanics of the heart, while pharmaceutical industry partners bring deep understanding of the mechanisms of drug actions. The results will demonstrate the value of the VPH initiative to fundamental scientific understanding of the heart, with major economic and clinical impacts through accelerated drug development, approvaland use.

Consortium · 9 organisations

coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

UK · €2,121,143

participant

AUREUS PHARMA SA

FR · €765,000

participant

CENTRO DI RICERCA, SVILUPPO E STUDI SUPERIORI IN SARDEGNA SOCIETÀ A RESPONSABILITÀ LIMITATA

IT · €327,600

participant

GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

UK

participant

NOVARTIS PHARMA AG

CH

participant

F. HOFFMANN-LA ROCHE AG

CH

participant

FUJITSU LABORATORIES OF EUROPE LIMITED

UK · €299,546

participant

UNIVERSITAT POLITECNICA DE VALENCIA

ES · €517,211

participant

SZEGEDI TUDOMANYEGYETEM

HU · €69,500

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.